Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2003
11/06/2003WO2003091432A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003WO2003091424A1 Method of screening agonistic antibody
11/06/2003WO2003091387A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
11/06/2003WO2003091271A1 Alternatively spliced nucleic acid molecules
11/06/2003WO2003091266A2 Protein stabilisation using chaperone proteins
11/06/2003WO2003091260A1 Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
11/06/2003WO2003091259A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003WO2003091258A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003091257A1 [1,4]DIAZOCINO [7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS
11/06/2003WO2003091251A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-1j]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003WO2003091250A1 [1,4]diazepino[6,7,1-ij]quinoline derivatives as anti psychotic and antiobesity agents
11/06/2003WO2003091249A1 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders
11/06/2003WO2003091248A1 Benzoxazinone derivative
11/06/2003WO2003091247A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003WO2003091244A1 New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
11/06/2003WO2003091243A1 Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
11/06/2003WO2003091241A1 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
11/06/2003WO2003091239A1 Estrogen receptor modulators
11/06/2003WO2003091236A1 Imidazolinylmethyl aralkylsulfonamides
11/06/2003WO2003091227A1 Tachykinin receptor antagonists
11/06/2003WO2003091226A1 Triazole derivatives as tachykinin receptor antagonists
11/06/2003WO2003091225A1 Substituted pyrazine derivatives
11/06/2003WO2003091223A1 Pyrimidine derivative
11/06/2003WO2003091220A1 Muscarinic antagonists
11/06/2003WO2003091219A1 Isoquinoline derivatives
11/06/2003WO2003091204A1 Phenethanolamine derivatives
11/06/2003WO2003091201A1 Dl-hydroxy-alkyl-phenylamides having anticonvulsive activity
11/06/2003WO2003091194A1 Hyperforin derivatives, the use thereof and formulations containing them
11/06/2003WO2003091193A1 Hyperforin halogenated derivatives, the use thereof and formulations containing them
11/06/2003WO2003091189A1 Cannabinoids
11/06/2003WO2003090775A1 Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning
11/06/2003WO2003090772A1 Method for treating anxiety and mood disorders in older subjects
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090751A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090743A1 Prevention and treatment of functional somatic disorders, including stress-related disorders
11/06/2003WO2003090738A1 Stress inhibition composition, theanine-containing granule and process for producing the same
11/06/2003WO2003090729A1 Transdermal analgesic systems with reduced abuse potential
11/06/2003WO2003090726A2 Chewable soft capsule
11/06/2003WO2003090697A2 Chimeric hybrid analgesics
11/06/2003WO2003090695A2 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
11/06/2003WO2003090689A2 Neurodegenerative disorder treatment using gdnf secreting neural cells
11/06/2003WO2003090671A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003WO2003090665A2 Regulation of erythrocyte apoptosis
11/06/2003WO2003080125A3 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
11/06/2003WO2003070171A3 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
11/06/2003WO2003066889A3 Assay for acytyltransferase or deacetylase activity
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003055983A3 Targeted retrograde gene delivery to motor neurons
11/06/2003WO2003055880A3 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
11/06/2003WO2003054009A3 Apoptotically active peptides
11/06/2003WO2003046570A3 Glycoprotein and apolipoprotein biopolymer markers predictive of alzheimers disease
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003035005A3 Heteroindanes: a new class of potent cannabimimetic ligands
11/06/2003WO2003034900A3 Sterile, breathable patch for treating wound pain
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003026700A3 Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases
11/06/2003WO2003024397A3 Enhancement of learning and memory and treatment of amnesia
11/06/2003WO2003024393A3 Autologous t-cell vaccines materials and method
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003016270A3 Selective estrogen receptor modulators
11/06/2003WO2003014080A3 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
11/06/2003WO2003013549A3 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
11/06/2003WO2003009855A3 Organo-phosphorous compounds for activating gamma/delta t cells
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2002094799A3 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/06/2003WO2002092773A3 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/06/2003WO2002083083A3 Pharmaceutically active compounds and methods of use
11/06/2003WO2002080960A3 Treatment of neuropathologies associated with expression of tnf-alpha
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002075317A3 Screening for drugs against disorders associated with schizophrenia
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002069993A8 Pharmaceutical composition made of cannabis extracts
11/06/2003WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002046475A3 Method of detecting and treating tuberous sclerosis complex associated disorders
11/06/2003WO2002044210A3 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
11/06/2003WO2002038208A9 Device and method for the cessation of smoking
11/06/2003WO2002030408A3 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002005749A3 Crf2 ligands in combination therapy
11/06/2003WO2002003848A8 Method for opening the blood-brain barrier
11/06/2003US20030208082 Nitrogen compounds such as 4,5-diisopropyl-1-methyl-2-styryl -1H-imidazole, used as glutamate receptor antagonists, for prophylaxis of psychological disorders, as anxiolytic agents and analgesics
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030207943 Administering dopamine, serotonin, and norepinephrine reuptake inhibitor (sibutramine) for treatment of neuropsychiatric disorders
11/06/2003US20030207939 Novel 3-substituted urea derivatives and medicinal use thereof
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207931 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1h-1,2,4-triazole for the treatment of autoimmune diseases
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207917 1,4-di-substituted piperidines, some of which have M2 selectivity even higher than that of 3-alpha-chloroimperialine for treating cognitive disorders such as Alzheimer's disease
11/06/2003US20030207913 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
11/06/2003US20030207911 For treatment of disease associated with the adenosine A2 receptor such as Alzheimer's disease and Parkinson's disease
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207905 Method of treating pain using nalbuphine and opioid antagonists
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207900 2-substituted amino-bicyclic pyridine and pyrimidine compounds; for treatment of inflammation, inflammatory bowel disease, Alzheimer's disease, Crohn's disease, multiple sclerosis and asthma
11/06/2003US20030207898 Sulfides such as N-(2-(((6- chloro-1,3-benzodioxol-5-yl)methyl )thio)phenyl)thiophene-2-carboxamide used for controlling metabolism of lipids and prophylaxis of diabetes, Alzheimers disease, atherosclerosis, dyslipidemia and genetic disorders
1 ... 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 ... 1833